glp 1 agonist vs sglt2 inhibitor GLP-1 Receptor Agonists and Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Drugs APhA 2025: GLP-1 Receptor Agonists

Updated timeline: May 2026: TRIUMPH-1 Phase 3 topline results announced Late 20262027: Remaining TRIUMPH trials complete

These preclinical findings support the further development and advancement of these small molecules as potential therapies for type 2 diabetes and obesity

GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

In hindsight, I was so fortunate to be at the right place and time to benefit from the opportunity to work on the proglucagon gene' (Bagley

42) In SUSTAIN-6, patients treated with semaglutide had a lower risk of developing or worsening nephropathy, but a higher risk of complications from diabetic retinopathy than those receiving placebo (40)

GLP-1 is also secreted by -cells of the pancreas and the central nervous system (CNS)